About 4D Molecular Therapeutics, Inc.
https://www.4dmoleculartherapeutics.com4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
CEO
David H. Kirn
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 92
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
Roth Capital
Buy
Goldman Sachs
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.9M
Value:$42.9M
BVF INC/IL
Shares:4.63M
Value:$40.55M
RA CAPITAL MANAGEMENT, L.P.
Shares:4.56M
Value:$39.97M
Summary
Showing Top 3 of 140
About 4D Molecular Therapeutics, Inc.
https://www.4dmoleculartherapeutics.com4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $90K ▲ | $14.04M ▲ | $-56.88M ▼ | -63.2K% ▲ | $-1.01 ▼ | $-55.62M ▲ |
| Q2-2025 | $15K ▲ | $11.52M ▼ | $-54.66M ▼ | -364.39K% ▼ | $-0.98 ▼ | $-58.29M ▼ |
| Q1-2025 | $14K ▲ | $53.63M ▼ | $-47.97M ▲ | -342.66K% ▲ | $-0.86 ▲ | $-51.87M ▲ |
| Q4-2024 | $1K ▼ | $54.33M ▲ | $-49.67M ▼ | -4.97M% ▼ | $-0.9 ▼ | $-61.04M ▼ |
| Q3-2024 | $3K | $51.13M | $-43.84M | -1.46M% | $-0.79 | $-49.43M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $305.06M ▲ | $423.98M ▼ | $55M ▲ | $368.98M ▼ |
| Q2-2025 | $293.23M ▼ | $473.64M ▼ | $52.75M ▲ | $420.89M ▼ |
| Q1-2025 | $321.44M ▼ | $515.73M ▼ | $46.01M ▼ | $469.72M ▼ |
| Q4-2024 | $424.88M ▼ | $560.38M ▼ | $49.78M ▼ | $510.61M ▼ |
| Q3-2024 | $501.89M | $604.03M | $51.08M | $552.95M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-56.88M ▼ | $-46.5M ▼ | $17.78M ▲ | $116K ▼ | $-28.6M ▲ | $-46.41M ▼ |
| Q2-2025 | $-54.66M ▼ | $-43.38M ▲ | $-13.85M ▼ | $862K ▲ | $-63.8M ▼ | $-43.44M ▲ |
| Q1-2025 | $-47.97M ▲ | $-47.76M ▼ | $31.95M ▲ | $0 ▼ | $-15.81M ▲ | $-48.39M ▼ |
| Q4-2024 | $-49.67M ▼ | $-45.86M ▼ | $7.06M ▼ | $601K ▲ | $-38.2M ▼ | $-46.81M ▼ |
| Q3-2024 | $-43.84M | $-29.39M | $27.3M | $568K | $-1.52M | $-31.17M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration And License Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2024 | Q3-2024 | Q1-2024 |
|---|---|---|---|---|
 NETHERLANDS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
David H. Kirn
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 92
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Chardan Capital
Buy
Roth Capital
Buy
Goldman Sachs
Buy
B of A Securities
Buy
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.9M
Value:$42.9M
BVF INC/IL
Shares:4.63M
Value:$40.55M
RA CAPITAL MANAGEMENT, L.P.
Shares:4.56M
Value:$39.97M
Summary
Showing Top 3 of 140